# A Study of LY3209590 in Participants With Type 2 Diabetes

> **NCT03367377** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 70 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** LY3209590
- **DRUG:** Insulin Glargine

## Key facts

- **NCT ID:** NCT03367377
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-03
- **Primary completion:** 2018-10-03
- **Final completion:** 2018-10-03
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2018-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03367377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03367377, "A Study of LY3209590 in Participants With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03367377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*